That was at least the reactions I experienced when I tried

New Post Public Reply Private Reply Replies (1) Message Board
trding Cytodynamite #12207
931
Quote:
That was at least the reactions I experienced when I tried to tell others about this company. A company being able to cure or at least treat HIV, Cancer, NASH etc sitting on OTC and being worth only $200m. *lol*


Quote:
As you said more than 800 patients with no side effects, no metastasis in cancer, shrunk tumor.....I mean that's real.



I see some issues with your sales pitch. Leronlimab doesn't cure HIV, Cancer or NASH. Leronlimab has side effects. There is an animal study that has yet to be published where we suspect leronlimab was used in connection with other techniques to cure monkey of SIV, but it blocks HIV from entry into the new cells. Cells already infected with HIV, leronlimab can't help. It can block the VL they produce from infecting other cells. This is maraviroc's downfall, those cells already infected can create a new mutated version on HIV which can infect cells maraviroc protects. Then this new version takes over. With leronlimab, it blocks essentially all r5. So any new mutations can't take hold. With patients on mono p2 trial that failed, they checked to make sure the virus had not mutated, and it hadn't, no chance with rebound group from start to after rebound, which is very very important if they want mono approval.

from mono paper, https://www.ncbi.nlm.nih.gov/pubmed/29676212

Quote:
There was no significant change in viral susceptibility to PRO 140 in virologic rebound and non-virologic rebound groups of patients assessed by post-treatment IC50, and IC90 values when compared with pretreatment baseline values. This indicates that the ligand-receptor recognition profile of the CCR5 co-receptor was not altered during the course of the study. In addition, no changes in HIV-1 co-receptor tropism following virologic rebound were seen. PhenoSense® Entry results for PRO 140, maraviroc, and AMD3100 showed no significant change in post-treatment IC50, and IC90, compared with baseline results in virologic rebound patients. However, there was a noted difference in the IC90 values from virologic rebound (10.8+/−9.28) and non virologic rebound (6.7+/−6.8) groups on entry analysis indicating that more PRO 140 was required to reach IC90 by the group that was destined to rebound on PRO 140 monotherapy.



Leronlimab has been proven in combo, the p3 trial is over with over 80% efficacy at 24 weeks, with the previous approved drugs in the same unmet need area hit around 40%.

Leronlimab mono is pulling good numbers, but still needs a p3 trial. This being approved doesn't help BP's bottom line already in HIV. They are happy to sit back and watch cydy do all the heavy lifting, knowing they can step in at the end and take over, especially if the market cap continues to stay this low.

Leronlimab has only one patient with tnbc so far, historically about 3% (I believe) of phase 2 cancer drugs make it to approval. I'm very exited even with the low success rate of the past in other drugs, because there is 20 years worth of research connecting ccr5 with cancer, hundreds of papers, researchers all over the world. And a p1 trial in maraviroc already with positive results.

Leronlimab in nash, not as many papers, not even close with nash and ccr5, then comparing cancer with ccr5. So I'm not as convinced here as with cancer. It not to say it doesn't work, just the cancer research is very solid connecting ccr5 and rantes and ccr5 antagonist to aiding cancer.

All drugs have side-effects. Leronlimab has no SAE, serious adverse events in over 800 patients (no life threatening events due to the drug). That is rare in HIV and cancer. Few people taking leronlimab have reported mild injection site reaction, but these usually that goes away, and no one has stopped the trial. Also similar to placabo percentages, headache, nausea, and diarrhea has been reported, again mild that goes away, possibly no connection, but might be listed as possible side effects I am guessing. But nothing compared to the side-effects some people are experiencing with other haart drugs, which is why I feel people will gravitate towards the drug with fewer side effects.

Here is safety comments in combo poster
https://content.equisolve.net/_f8eaae214fb1b6...c8e1bd.pdf

Generally well-tolerated
No discontinuation due to AEs
No pattern of toxicity
Administration-site reactions were infrequent, mild, transient, and self-resolving (in <10% of subjects)
No dose-limiting toxicity in preclinical or clinical studies

But here is from the mono poster
https://content.equisolve.net/_f8eaae214fb1b6...c8e1bd.pdf

Overall,the majority of AEs were considered mild in nature and there were no patterns of drug-related toxicities observed.

Approximately 95% of injection site reactions were mild in intensity and considered to be self-resolving

No dose proportional increase inincidence and severity of AEs were reported with higher doses of PRO140(leronlimab).

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 16

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 150

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 132

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 127

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 91

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 28

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 208

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 213

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 144

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading

Top 5 Most Recently Viewed Articles

PHX Minerals Set to Release Full-Year 2024 Financial Results

Updated Category News Views 176

PHX Minerals Reveals Upcoming Financial Results Announcement PHX MINERALS INC., commonly known as PHX, is preparing to share its financial results for the year that concluded on December 31, 2024. This announcement is eagerly awaited by investors and stakeholders, marking a significant moment in understanding the company’s financial health and future outlook. Details of...

Continue Reading
Baird Optimistic on First Industrial Realty Trust Growth Ahead

Updated Category News Views 183

Baird's Positive Outlook for First Industrial Realty Trust Baird has reaffirmed its positive stance on First Industrial Realty Trust (NYSE: FR), maintaining an Outperform rating alongside a $61.00 price target. The firm's analysis indicates that the company's core portfolio is projected to deliver a stable 6% annual growth, signaling strong performance prospects for...

Continue Reading
Aprea Therapeutics Secures $3.1 Million Investment for Growth

Updated Category News Views 151

Aprea Therapeutics Secures $3.1 Million Investment Aprea Therapeutics, Inc. (Nasdaq: APRE), a forward-thinking clinical-stage biopharmaceutical company, has announced a notable private placement aimed at enhancing its development of innovative cancer treatments. This financing comes from a blend of new and existing investors, reflecting confidence in the company’s...

Continue Reading
Silal and SVG Forge New Paths in Sustainable Agriculture

Updated Category News Views 174

Silal and SVG Forge New Paths in Sustainable Agriculture In a significant development for the agricultural sector, Silal, a leading agri-food and technology company, and Shouguang Colorful Manor Modern Agriculture Co., Ltd (SVG) have entered a joint venture that stands to revolutionize sustainable agriculture practices. This landmark agreement was witnessed by eminent...

Continue Reading